Lupin Limited — Updates, 26-05-2025: Press Release

Lupin has partnered with Latin America’s SteinCares to commercialize its biosimilar ranibizumab across the region, excluding Mexico and Argentina. Lupin will manufacture the drug, while SteinCares handles regulatory approvals and distribution. This collaboration targets expansion in the biosimilar retinal disease market, enhancing Lupin’s regional footprint and increasing access to advanced treatments for conditions like Wet AMD and diabetic retinopathy.